Literature DB >> 21225252

CYP2D6 genotyping by liquid chromatography-electrospray ionization mass spectrometry.

Beate Beer1, Robert Erb, Florian Pitterl, Harald Niederstätter, Olalla Maroñas, Alejandro Gesteira, Angel Carracedo, Irina Piatkov, Herbert Oberacher.   

Abstract

Genetic polymorphisms can significantly affect the enzyme activity of the drug metabolizing enzyme Cytochrome P450 2D6 (CYP2D6; OMIM 124030). Accordingly, CYP2D6 genotyping is considered as a valid approach to predict the individual CYP2D6 metabolizing status. We introduce ion-pair reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry (ICEMS) as method for the characterization of single base variants, small deletions, and insertions in the CYP2D6 gene. A two-step polymerase chain reaction (PCR) was developed for the simultaneous amplification of nine polymorphic regions within the CYP2D6 gene. Cleanup, separation, and denaturation of PCR amplicons were achieved by high-performance liquid chromatography. High-performance molecular mass measurements provided nucleotide composition profiles that principally enable the resolution of 37 reported CYP2D6 alleles. The developed assay was applied to the genotyping of 93 unrelated Austrian individuals. For validation, a selected number of samples and polymorphic sites were retyped by alternative genotyping technologies. The PCR-ICEMS assay turned out to be an accurate, robust, and cost-effective CYP2D6 genotyping strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21225252     DOI: 10.1007/s00216-010-4597-4

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  8 in total

1.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

Review 2.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action.

Authors:  Shan Zhao; Ravi Iyengar
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012       Impact factor: 13.820

3.  The Genetic Variation of CYP2D6 Gene in the Bosnian Population.

Authors:  Hilada Nefic
Journal:  Med Arch       Date:  2018-12

Review 4.  Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.

Authors:  Yitian Zhou; Volker M Lauschke
Journal:  Hum Genet       Date:  2021-10-15       Impact factor: 5.881

5.  Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study.

Authors:  Beate Beer; Robert Erb; Marion Pavlic; Hanno Ulmer; Salvatore Giacomuzzi; Yvonne Riemer; Herbert Oberacher
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

6.  Genetic polymorphisms analysis of CYP2D6 in the Uygur population.

Authors:  Xue He; Na He; Lisong Ren; Yongri Ouyang; Ning Zhang; Yini Ma; Dongya Yuan; Longli Kang; Tianbo Jin
Journal:  BMC Genomics       Date:  2016-05-26       Impact factor: 3.969

7.  Improved Polymerase Chain Reaction-restriction Fragment Length Polymorphism Genotyping of Toxic Pufferfish by Liquid Chromatography/Mass Spectrometry.

Authors:  Hajime Miyaguchi
Journal:  J Vis Exp       Date:  2016-09-20       Impact factor: 1.355

8.  Clinical Relevance of CYP2D6 Polymorphisms in Patients of an Austrian Medical Practice: A Family Practice-Based Observational Study.

Authors:  Gustav Kamenski; Seda Ayazseven; Anne Berndt; Waltraud Fink; Lukas Kamenski; Sonja Zehetmayer; Helene Pühringer
Journal:  Drugs Real World Outcomes       Date:  2020-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.